Serotonin 1A Receptor Binding of [11C]CUMI-101 in Bipolar Depression Quantified Using Positron Emission Tomography: Relationship to Psychopathology and Antidepressant Response.
Martin J Lan, Francesca Zanderigo, Spiro P Pantazatos, M Elizabeth Sublette, Jeffrey Miller, R Todd Ogden, J John Mann
Author Information
Martin J Lan: Department of Psychiatry, Vagelos College of Physicians and Surgeons at Columbia University, New York, NY, USA.
Francesca Zanderigo: Department of Psychiatry, Vagelos College of Physicians and Surgeons at Columbia University, New York, NY, USA.
Spiro P Pantazatos: Department of Psychiatry, Vagelos College of Physicians and Surgeons at Columbia University, New York, NY, USA.
M Elizabeth Sublette: Department of Psychiatry, Vagelos College of Physicians and Surgeons at Columbia University, New York, NY, USA.
Jeffrey Miller: Department of Psychiatry, Vagelos College of Physicians and Surgeons at Columbia University, New York, NY, USA.
R Todd Ogden: Department of Psychiatry, Vagelos College of Physicians and Surgeons at Columbia University, New York, NY, USA.
J John Mann: Department of Psychiatry, Vagelos College of Physicians and Surgeons at Columbia University, New York, NY, USA.
BACKGROUND: The pathophysiology of bipolar disorder (BD) remains largely unknown despite it causing significant disability and suicide risk. Serotonin signaling may play a role in the pathophysiology, but direct evidence for this is lacking. Treatment of the depressed phase of the disorder is limited. Previous studies have indicated that positron emission tomography (PET) imaging of the serotonin 1A receptor (5HT1AR) may predict antidepressant response. METHODS: A total of 20 participants with BD in a current major depressive episode and 16 healthy volunteers had PET imaging with [11C]CUMI-101, employing a metabolite-corrected input function for quantification of binding potential to the 5HT1AR. Bipolar participants then received an open-labeled, 6-week clinical trial with a selective serotonin reuptake inhibitor (SSRI) in addition to their mood stabilizer. Clinical ratings were obtained at baseline and during SSRI treatment. RESULTS: Pretreatment binding potential (BPF) of [11C]CUMI-101 was associated with a number of pretreatment clinical variables within BD participants. Within the raphe nucleus, it was inversely associated with the baseline Montgomery Åsberg Rating Scale (P = .026), the Beck Depression Inventory score (P = .0023), and the Buss Durkee Hostility Index (P = .0058), a measure of lifetime aggression. A secondary analysis found [11C]CUMI-101 BPF was higher in bipolar participants compared with healthy volunteers (P = .00275). [11C]CUMI-101 BPF did not differ between SSRI responders and non-responders (P = .907) to treatment and did not predict antidepressant response (P = .580). Voxel-wise analyses confirmed the results obtained in regions of interest analyses. CONCLUSIONS: A disturbance of serotonin system function is associated with both the diagnosis of BD and its severity of depression. Pretreatment 5HT1AR binding did not predict SSRI antidepressant outcome.The study was listed on clinicaltrials.gov with identifier NCT02473250.
